SCHEMBL21322925

SCHEMBL21322925

O=C(CCc1ccccc1)N1CC2CN(C(=O)c3ccc4[nH]nnc4c3)CC2C1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KDM5C P41229 4/20 0.43
▸ KDM4C Q9H3R0 4/20 0.43
▸ KDM2A Q9Y2K7 3/20 0.43
▸ KDM4A O75164 2/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ NPC1 O15118 3/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ ENPP2 Q13822 3/20 0.40
▸ ATXN2 Q99700 2/20 0.40
▸ POLB P06746 2/20 0.40
▸ RAB9A P51151 2/20 0.39
▸ HPGD P15428 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ KDM6B O15054 2/20 0.39
▸ KDM3A Q9Y4C1 2/20 0.39
▸ FKBP1A P62942 1/20 0.39
▸ TSHR P16473 1/20 0.38
▸ DDR1 Q08345 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16963777 1.00 KDM5C (0.43) KDM5CKDM4CKDM2AKDM4AKDM4E
SCHEMBL18540872 0.94 NAAA (0.45) KDM5CKDM4CKDM2AKDM4AKDM4E
SCHEMBL16962981 0.94 NAAA (0.45) KDM5CKDM4CKDM2AKDM4AKDM4E
SCHEMBL21323059 0.88 ENPP2 (0.52) ENPP2ATXN2HPGD
SCHEMBL16962855 0.88 ENPP2 (0.52) ENPP2ATXN2HPGD
SCHEMBL21323107 0.88 LSS (0.39) ENPP2ATXN2
SCHEMBL21323349 0.88 ENPP2 (0.43) KDM4EENPP2ATXN2HPGD
SCHEMBL16963841 0.88 LSS (0.39) ENPP2ATXN2
SCHEMBL16962369 0.88 ENPP2 (0.43) KDM4EENPP2ATXN2HPGD
SCHEMBL21322941 0.87 KDM5C (0.41) KDM5CKDM4CKDM2AKDM4AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2900669-B1 HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES AND RELATED COMPOUNDS AS AUTOTAXIN (ATX) INHIBITORS AND AS INHIBITORS OF THE LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION FOR TREATING E.G. RENAL DISEASES HOFFMANN LA ROCHE (CH) 2019-09-04 — — EP disclosed
Send feedback